IN THE CLAIMS

Please cancel Claims 1-17.

Please add the following new claims.

18. (New) A method for the prophylaxis or treatment of a respiratory disorder in a mammalian host by inhalation of a pre-metered dry powder combined dose of finely divided dry medication powders, comprising:

selecting at least one first dry powder medicament from a first group of bronchodilating medicaments and at least one second dry powder medicament from a second group of anti-inflammatory medicaments;

preparing a metered pre-metered dry powder medicinal combined dose comprising separately metered deposits by depositing separate, pre-metered, medicinally suitable effective quantities of at least one of each of the first and second groups of medicaments on selected target areas of a common dose bed, where the sum of the metered pre-metered deposits constitutes the metered pre-metered quantity of powder of the medicinal combined dose;

sealing the combined dose from ingress of moisture; and

introducing the medicinal combined dose into an inhaler device for delivery of the medicinal combined dose during the course of a single inhalation by a user, wherein the delivered medicinal combined dose, when delivered, comprises mixed de-aggregated fine particles of the selected medicaments.

19. (New) The method according to claim 18, wherein the first medicament comprises formoterol, a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or a mixtures thereof and the second medicament comprises budesonide, a

pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or a mixtures thereof.

20. (New) The method according to claim 18, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the second medicament.

21. (New) The method according to claim 18, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixtures thereof is selected as the second medicament.

22. (New) The method according to claim 18, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixture thereof is selected as the first medicament and ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, solvate, or mixture thereof is selected as the second medicament.

23. (New) The method according to claim 18, wherein one or more of Albuterol, Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium, Tulobuterol, pharmaceutically acceptable salts, enantiomers, racemates, hydrates, and solvates thereof, and mixtures thereof is selected as the first medicament and one or more of Budesonide,

Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone, Triamcinolone, pharmaceutically acceptable salts, enantiomers, racemates, hydrates, solvates thereof, and mixtures thereof is selected as the second medicament.

24. (New) The method according to claim 18, wherein the dry powder medicinal combined dose has a total mass of 10 μg to 50 mg.

25. (New) The method according to claim 18, further comprising separating the deposits of the medicaments from each other onto the dose bed, such that the medicaments cannot detrimentally mix with each other after forming of the combined dose.

26. (New) The method according to claim 18, further comprising administering said combined dose via a continuous dry powder inhaler (DPI) designed for a prolonged delivery of the medicinal combined dose to a user inhaling once through the DPI.

27. (New) A pharmaceutical dry powder combined dose, adapted for inhalation, for the prophylaxis or treatment of a respiratory disorder in a mammalian host, comprising at least one medicament from a first group of bronchodilating medicaments and at least one medicament from a second group of anti-inflammatory medicaments, wherein the pharmaceutical dry powder combined dose comprises separate, pre-metered deposits of a medicinally suitable quantity of the selected medicaments from the first and second groups of medicaments respectively on a common dose bed, where the sum of the deposits constitute the pre-metered quantity of powder in the pharmaceutical, combined dose, and where the combined dose is protected from ingress of moisture by a seal.

28. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the first medicament and budesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the second medicament.

29. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the first medicament and fluticasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the second medicament.

30. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the first medicament and mometasone or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the second medicament.

31. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein formoterol or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the first medicament and ciclesonide or a pharmaceutically acceptable salt, enantiomer, racemate, hydrate, or solvate thereof, or mixtures thereof is comprised as the second medicament.

32. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein one or more of Albuterol, Bambuterol, Bitolterol, Broxaterol, Carbuterol, Clenbuterol, Etanterol, Fenoterol, Formoterol, Hexoprenaline, Imoxiterol, Isoetharine, Metaproterenol, Naminterol, Picumeterol, Pirbuterol, Procaterol, Rimiterol, Reproterol, Salmeterol, Terbutaline, Tiotropium, Tulobuterol, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof is comprised as the first medicament and one or more of Budesonide, Beclomethasone, Ciclesonide, Dexametasone, Flunisolide, Fluticasone, Ipratropium, Mometasone, Triamcinolone, pharmaceutically acceptable salts, enantiomers, racemates hydrates, or solvate thereof, or mixtures thereof is comprised as the second medicament.

33. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein the combined dose has a total mass in a range from 10 μg to 50 mg.

34. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein the included medicaments are separated from each other onto the dose bed, such that the medicaments cannot detrimentally mix with each other upon forming a combined dose.

35. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein the pre-metered medicaments are deposited onto the common dose bed to form a medicinal combined dose having a general elongated shape.

36. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein each of the pre-metered medicaments is deposited in a respective separate compartment of the common dose bed.

37. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein a biologically acceptable, inert substance is deposited between the deposits of the medicaments to prevent the medicaments from interacting detrimentally after forming of the combined dose.

38. (New) The pharmaceutical dry powder combined dose according to claim 27, wherein the medicinal combined dose is adapted for delivery from a dry powder inhaler device during the course of a single inhalation by gradual aerosolization of the combined dose in the form of a relative motion between an air-sucking nozzle and the common dose bed.